Metabolic Dysfunction-Associated Steatotic Liver Disease and Mitochondrial Quality Control: From Laboratory to Clinical Practice
Frontiers in Bioscience-Landmark · 2026
DOI: 10.31083/fbl41721 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, 2026. Verfasst von Wenkai Fu und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Third School of Clinical Medicine, Beijing University of Traditional Chinese Medicine, 100029 Beijing, China. Hauptthemen laut MEDLINE: Mitochondria, Fatty Liver, Non-alcoholic Fatty Liver Disease, Metabolic Diseases. Die Arbeit nennt 209 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Innovation Key Project of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, The Innovation Key Project of Guang’anmen Hospital, China Academy of Chinese Medical Sciences.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects more than 1.66 billion people globally. This metabolic disorder shows strong connections with mitochondrial dysfunction and disrupted mitochondrial quality control (MQC) processes. Our review systematically analyzes the molecular mechanisms underlying the relationship between MQC and MASLD development. Research evidence indicates that impaired MQC regulation worsens three key pathological conditions: it intensifies liver fat accumulation, increases oxidative damage, and promotes inflammatory cell death through activating inflammatory signaling pathways, boosting reactive oxygen species generation, and triggering programmed cell death in hepatocytes. Current pharmacological interventions have shown mixed effects. Metformin, resveratrol, and empagliflozin have moderating effects on MQC homeostasis in experimental models, but their clinical application remains limited. The review further predicts two key systemic impacts of MASLD: it amplifies cardiovascular disease risk through links between organ systems, and it highlights the need to develop targeted regulation of the gut microbiota. Three major research challenges require urgent attention: first, clarifying the complex interactions between different MQC pathways; second, establishing clinical effectiveness through human trials; third, bridging the gap between laboratory findings and practical medical interventions. These priorities highlight the need for coordinated multidisciplinary research efforts to address this growing public health challenge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Third School of Clinical Medicine, Beijing University of Traditional Chinese Medicine, 100029 Beijing, China.
- Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong (CUHK), Hong Kong SAR, China.
- State Key Laboratory of Traditional Chinese Medicine Syndrome, Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, 510006 Guangzhou, Guangdong, China.
- Cardiology, Senior Department of Cardiology, PLA General Hospital, 100048 Beijing, China.
- Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, 100053 Beijing, China.
- Gastroenterology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, 100053 Beijing, China.
Förderung
- The Innovation Key Project of Guang'anmen Hospital, China Academy of Chinese Medical Sciences
- The Innovation Key Project of Guang’anmen Hospital, China Academy of Chinese Medical Sciences
Zitieren
APA
Fu, W., Wang, J., Lu, N., Guo, Z., Ong, S. B., Gao, Y., Zhou, H., Chang, X., & Meng, M. (2026). Metabolic Dysfunction-Associated Steatotic Liver Disease and Mitochondrial Quality Control: From Laboratory to Clinical Practice. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl41721
Vancouver
Fu W, Wang J, Lu N, Guo Z, Ong SB, Gao Y, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease and Mitochondrial Quality Control: From Laboratory to Clinical Practice. Frontiers in Bioscience-Landmark. 2026. doi:10.31083/fbl41721
BibTeX
@article{Fu2026,
author = {Fu, Wenkai and Wang, Junqi and Lu, Nan and Guo, Zhijiang and Ong, Sang-Bing and Gao, Yong and Zhou, Hao and Chang, Xing and Meng, Miao},
title = {Metabolic Dysfunction-Associated Steatotic Liver Disease and Mitochondrial Quality Control: From Laboratory to Clinical Practice},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
doi = {10.31083/fbl41721}
}
EUVIMED